Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for SparVax(TM). At this point there can be no assurance that SparVax(TM) will be shown to be safe and effective and approved by regulatory authorities for use in humans.

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, ... using the genome to create better medicine, today congratulated the ... studies of whole-genome data yet undertaken. The ... – are built around the most comprehensive population-wide ... of deCODE scientists led by Kari Stefansson , deCODE,s ...
(Date:3/25/2015)... 2015 Having added two International locations ... of 2014, ITRA Global proudly announced recently the organization’s ... Representative Alliance, based in the United States, is one ... occupiers of commercial real estate. , Saltwood International ... Poland that exclusively advises occupiers of office space, ensuring ...
(Date:3/25/2015)... TORONTO , March 25, 2015 /CNW/ - ... winners of the 2015 Canada Gairdner Awards, recognizing some ... the world. Among the world,s ... a leader in science and provide a $100,000 (CDN) prize ... promote a stronger culture of research and innovation ...
(Date:3/25/2015)... 25, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announces ... its target therapy drug candidate ENMD-2076 in triple-negative breast ... of Medical Sciences in Beijing , ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2International Organization Expands its Global Reach to Warsaw, Poland 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 42015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 52015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 62015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 72015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 8CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 4CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 5
... Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/,-- Curis, ... development company focused on,developing proprietary targeted medicines for ... companies with a focus on the development of,prescription ... that they,have entered into a worldwide, exclusive license ...
... China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced the appointment of Mr.,William Wei Lee as an ... effective August 4, 2009. Mr. Jiang Qi-Feng resigned from ...
... 6 Interleukin Genetics, Inc. (NYSE Amex: ... conference call and webcast on Thursday, August 13, 2009, at 4:30 ... financial results. , , To access the live ... replay access of the teleconference will be available on the Investors ...
Cached Biology Technology:Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 2Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 3Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 4Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 5Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 6China Sky One Medical, Inc. Appoints New Independent Director 2China Sky One Medical, Inc. Appoints New Independent Director 3
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
(Date:3/10/2015)... , March 10, 2015 ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured ... the past two years. Specifically, "Personalized Medicine ... downloaded scientific papers published in 2013 and 2014 from ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... WASHINGTON, Oct. 18 Can skin cancer be treated ... Irvine), believe so. They,re exploring new ways to image cancerous ... cancer called photodynamic therapy (PDT) -- work that they will ... in Optics (FiO) 2010 at the Rochester Riverside Convention ...
... Health (NIH) have determined the complete genetic blueprints for ... bacteria that cause Lyme disease. The achievement should lead ... strains may result in different courses of illness in ... in North America. The wealth of new genetic data ...
... University of Michigan Heath System and their collaborators have ... help guide new treatments for psoriasis, one of the ... Using cutting-edge methods to peer into the hidden genetic ... published in Nature Genetics, further maps the ...
Cached Biology News:Treating cancer with light 2Four new psoriasis 'hotspots' identified by U-M geneticists 2
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. A ... Has reduced electrostatic interactions that do not ... Aggregation number: 8-16. Purity: ≥95% by ... Aggregation number 8 - 16, CMC 1.1 ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... Goat polyclonal to PAX3 This protein ... (PAX) family of transcription factors. Members of ... box domain and a paired-type homeodomain. These ... Mutations in paired box gene 3 are ...
Biology Products: